4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Catalyst Pharmaceuticals, Inc. (CPRX) operates in the Biotechnology industry and is headquartered in Coral Gables, United States with about 182 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, CPRX reported $589M in revenue and $214M in net income.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
Interactive charts & full statements → Open the CPRX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $589M | $492M | $398M | $214M | — |
| Gross Profit | $502M | $423M | $346M | $180M | — |
| Operating Income (EBIT) | $258M | $195M | $87M | $102M | — |
| Net Income | $214M | $164M | $71M | $83M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $149M | $153M | $148M | $147M | $141M | — |
| Gross Profit | $135M | $126M | $126M | $126M | $124M | — |
| Operating Income (EBIT) | $73M | $62M | $66M | $66M | $63M | — |
| Net Income | $64M | $53M | $53M | $52M | $57M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $1.1B | $851M | $470M | $376M | — |
| Total Liabilities | $150M | $124M | $82M | $75M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CPRX viewer.
About TickerBase · Data methodology & sources